{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:53:26Z","timestamp":1785916406436,"version":"3.56.0"},"reference-count":241,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Monoclonal antibodies (mAbs) directed against antigen-specific of multiple myeloma (MM) cells have Fc-dependent immune effector mechanisms, such as complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP), but the choice of the antigen is crucial for the development of effective immuno-therapy in MM. Recently new immunotherapeutic options in MM patients have been developed against different myeloma-related antigens as drug conjugate-antibody, bispecific T-cell engagers (BiTEs) and chimeric antigen receptor (CAR)-T cells. In this review, we will highlight the mechanism of action of immuno-therapy currently available in clinical practice to target CD38, SLAMF7, and BCMA, focusing on the biological role of the targets and on mechanisms of actions of the different immunotherapeutic approaches underlying their advantages and disadvantages with critical review of the literature data.<\/jats:p>","DOI":"10.3389\/fonc.2021.684561","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T08:28:57Z","timestamp":1625732937000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma"],"prefix":"10.3389","volume":"11","author":[{"given":"Alessandra","family":"Romano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Storti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Marchica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Scandura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Notarfranchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Craviotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"xi","DOI":"10.1016\/j.hoc.2014.08.001","article-title":"Multiple Myeloma","volume":"28","author":"Anderson","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/198539","article-title":"Immunological Dysregulation in Multiple Myeloma Microenvironment","volume":"2014","author":"Romano","year":"2014","journal-title":"BioMed Res Int"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/456037","article-title":"Salvage Therapy of Multiple Myeloma: The New Generation Drugs","volume":"2014","author":"Romano","year":"2014","journal-title":"BioMed Res Int"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.247015","article-title":"Multiple Myeloma: The (R)Evolution of Current Therapy and a Glance Into Future","volume":"105","author":"Gulla","year":"2020","journal-title":"Haematologica"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.14670\/HH-20.1227","article-title":"The Role of the Bone Marrow Microenvironment in Multiple Myeloma","volume":"20","author":"De Raeve","year":"2005","journal-title":"Histol Histopathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1624158","article-title":"Novel Targets for the Treatment of Relapsing Multiple Myeloma","volume":"12","author":"Giuliani","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2741\/4201","article-title":"CD38 and Bone Marrow Microenvironment","volume":"19","author":"Chillemi","year":"2014","journal-title":"Front Biosci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.critrevonc.2017.01.011","article-title":"Immunotherapy for the Treatment of Multiple Myeloma","volume":"111","author":"Jung","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1740084","article-title":"Monoclonal Antibodies in Relapsed\/Refractory Myeloma: Updated Evidence From Clinical Trials, Real-Life Studies, and Meta-Analyses","volume":"13","author":"Musto","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9093022","article-title":"Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma","volume":"9","author":"Dalla Palma","year":"2020","journal-title":"J Clin Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-625343","article-title":"Influence of Immunoglobulin Isotype on Therapeutic Antibody Function","volume":"127","author":"Beers","year":"2016","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/antib8020030","article-title":"The Ligands for Human IgG and Their Effector Functions","volume":"8","author":"de Taeye","year":"2019","journal-title":"Antibodies (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00410-0","article-title":"The Role of IgG Fc Receptors in Antibody-Dependent Enhancement","volume":"20","author":"Bournazos","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4049\/jimmunol.160.1.395","article-title":"Human CD38 (ADP-Ribosyl Cyclase) Is a Counter-Receptor of CD31, an Ig Superfamily Member","volume":"160","author":"Deaglio","year":"1998","journal-title":"J Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.3.1588","article-title":"Discrete Stages of Human Intrathymic Differentiation: Analysis of Normal Thymocytes and Leukemic Lymphoblasts of T-Cell Lineage","volume":"77","author":"Reinherz","year":"1980","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal Antibodies Targeting CD38 in Hematological Malignancies and Beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2008.02.005","article-title":"CD38 at the Junction Between Prognostic Marker and Therapeutic Target","volume":"14","author":"Deaglio","year":"2008","journal-title":"Trends Mol Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000058765","article-title":"CD38\/CD31, a Receptor\/Ligand System Ruling Adhesion and Signaling in Human Leukocytes","volume":"75","author":"Deaglio","year":"2000","journal-title":"Chem Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and Function of the ADP Ribosyl Cyclase\/CD38 Gene Family in Physiology and Pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol Rev"},{"key":"B20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/0167-4838(93)90113-6","article-title":"Wide Distribution of an Enzyme That Catalyzes the Hydrolysis of Cyclic ADP-Ribose","volume":"1164","author":"Lee","year":"1993","journal-title":"Biochim Biophys Acta (BBA) - Protein Structure Mol Enzymol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1993.1265","article-title":"Production and Hydrolysis of Cyclic ADP-Ribose at the Outer Surface of Human Erythrocytes","volume":"191","author":"Lee","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.6.2308.bloodjournal8762308","article-title":"Expression of Cyclic ADP-Ribose-Synthetizing CD38 Molecule on Human Platelet Membrane","volume":"87","author":"Ramaschi","year":"1996","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0404262","article-title":"CD38 Is Expressed Selectively During the Activation of a Subset of Mature T Cells With Reduced Proliferation But Improved Potential to Produce Cytokines","volume":"77","author":"Sandoval-Montes","year":"2005","journal-title":"J Leuk Biol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/Bf02591400","article-title":"Cd38 -\u00a0a Multilineage Cell Activation Molecule With a Split Personality","volume":"22","author":"Malavasi","year":"1992","journal-title":"Int J Clin Lab Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41581-018-0074-7","article-title":"Effector and Regulatory B Cells in Immune-Mediated Kidney Disease","volume":"15","author":"Oleinika","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-275610","article-title":"CD38 and Chronic Lymphocytic Leukemia: A Decade Later","volume":"118","author":"Malavasi","year":"2011","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17896","article-title":"Expression of CD38 in Myeloma Bone Niche: A Rational Basis for the Use of Anti-CD38 Immunotherapy to Inhibit Osteoclast Formation","volume":"8","author":"Costa","year":"2017","journal-title":"Oncotarget"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.123","article-title":"Upregulation of CD38 Expression on Multiple Myeloma Cells by All-Trans Retinoic Acid Improves the Efficacy of Daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/nyas.12485","article-title":"Unraveling the Contribution of Ectoenzymes to Myeloma Life and Survival in the Bone Marrow Niche","volume":"1335","author":"Quarona","year":"2015","journal-title":"Ann New York Acad Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509056827","article-title":"PECAM-1: Its Expression and Function as a Cell Adhesion Molecule on Hemopoietic and Endothelial Cells","volume":"17","author":"Watt","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121527","article-title":"CD38, a Receptor With Multifunctional Activities: From Modulatory Functions on Regulatory Cell Subsets and Extracellular Vesicles, to a Target for Therapeutic Strategies","volume":"8","author":"Morandi","year":"2019","journal-title":"Cells"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.51.30327","article-title":"ADP-Ribosyl Cyclase and CD38 Catalyze the Synthesis of a Calcium-Mobilizing Metabolite From NADP","volume":"270","author":"Aarhus","year":"1995","journal-title":"J Biol Chem"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25204844","article-title":"The Circular Life of Human CD38: From Basic Science to Clinics and Back","volume":"25","author":"Horenstein","year":"2020","journal-title":"Molecules"},{"key":"B34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical Efficacy of Daratumumab Monotherapy in Patients With Heavily Pretreated Relapsed or Refractory Multiple Myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0857-2","article-title":"A Dose-Finding Phase 2 Study of Single Agent Isatuximab (Anti-CD38 mAb) in Relapsed\/Refractory Multiple Myeloma","volume":"34","author":"Mikhael","year":"2020","journal-title":"Leukemia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30249-2","article-title":"MOR202, a Novel Anti-CD38 Monoclonal Antibody, in Patients With Relapsed or Refractory Multiple Myeloma: A First-in-Human, Multicentre, Phase 1-2a Trial","volume":"7","author":"Raab","year":"2020","journal-title":"Lancet Haematol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-360552","article-title":"A Phase 1, Multicenter, Open-Label, Dose Escalation Study of Elotuzumab in Patients With Advanced Multiple Myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.940.940","article-title":"Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Refractory Patient-Derived Multiple Myeloma Cells, Growing in a Novel Humanized Mouse MM Model","volume":"120","author":"Noort","year":"2012","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 Antibodies in Multiple Myeloma: Back to the Future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38<sup<+<\/sup< Hematologic Malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab Plus Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma (ICARIA-MM): A Randomised, Multicentre, Open-Label, Phase 3 Study (Vol 394, Pg 2096, 2019)","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01393","article-title":"Fc Gamma Receptors and Their Role in Antigen Uptake, Presentation, and T Cell Activation","volume":"11","author":"Junker","year":"2020","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/cells9010167","article-title":"Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma","volume":"9","author":"Saltarella","year":"2020","journal-title":"Cells"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3117","article-title":"Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo-Expanded Autologous NK Cells","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3418","article-title":"Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma","volume":"27","author":"Cho","year":"2021","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/srep34310","article-title":"CD16 Is Indispensable for Antibody-Dependent Cellular Cytotoxicity by Human Monocytes","volume":"6","author":"Yeap","year":"2016","journal-title":"Sci Rep"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16548","article-title":"CD14(+) CD16(+) Monocytes Are Involved in Daratumumab-Mediated Myeloma Cells Killing and in Anti-CD47 Therapeutic Strategy","volume":"190","author":"Storti","year":"2020","journal-title":"Br J Haematol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01771","article-title":"Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells","volume":"11","author":"Zhu","year":"2020","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1597","article-title":"The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0260","article-title":"Mechanism of Action of a New Anti-CD38 Antibody: Enhancing Myeloma Immunotherapy","volume":"25","author":"Malavasi","year":"2019","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-Mediated Phagocytosis Contributes to the Anti-Tumor Activity of the Therapeutic Antibody Daratumumab in Lymphoma and Multiple Myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"mAbs"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/science.1248943","article-title":"Complement Is Activated by IgG Hexamers Assembled at the Cell Surface","volume":"343","author":"Diebolder","year":"2014","journal-title":"Science"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz9356","article-title":"Structure of CD20 in Complex With the Therapeutic Monoclonal Antibody Rituximab","volume":"367","author":"Roug\u00e9","year":"2020","journal-title":"Science"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb8008","article-title":"Binding Mechanisms of Therapeutic Antibodies to Human CD20","volume":"369","author":"Kumar","year":"2020","journal-title":"Science"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab Depletes CD38+ Immune Regulatory Cells, Promotes T-Cell Expansion, and Skews T-Cell Repertoire in Multiple Myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.imlet.2018.04.005","article-title":"Immunomodulatory Effects of CD38-Targeting Antibodies","volume":"199","author":"van de Donk","year":"2018","journal-title":"Immunol Lett"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-3192","article-title":"Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/cells4030520","article-title":"NAD(+)-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model","volume":"4","author":"Horenstein","year":"2015","journal-title":"Cells"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.86","article-title":"Targeting Immunosuppressive Adenosine in Cancer","volume":"17","author":"Vijayan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/leu.2015.240","article-title":"SAR650984 Directly Induces Multiple Myeloma Cell Death via Lysosomal-Associated and Apoptotic Pathways, Which Is Further Enhanced by Pomalidomide","volume":"30","author":"Jiang","year":"2016","journal-title":"Leukemia"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.030759","article-title":"Towards Effective Immunotherapy of Myeloma: Enhanced Elimination of Myeloma Cells by Combination of Lenalidomide With the Human CD38 Monoclonal Antibody Daratumumab","volume":"96","author":"van der Veer","year":"2011","journal-title":"Haematologica"},{"key":"B64","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05286.x","article-title":"Molecular Mechanisms Whereby Immunomodulatory Drugs Activate Natural Killer Cells: Clinical Application","volume":"128","author":"Hayashi","year":"2005","journal-title":"Br J Haematol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-1813","article-title":"Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib","volume":"21","author":"Nijhof","year":"2015","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1038\/bcj.2011.42","article-title":"The Therapeutic Human CD38 Antibody Daratumumab Improves the Anti-Myeloma Effect of Newly Emerging Multi-Drug Therapies","volume":"1","author":"van der Veer","year":"2011","journal-title":"Blood Cancer J"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.8078","article-title":"Effect of MOR202, a Human CD38 Antibody, in Combination With Lenalidomide and Bortezomib, on Bone Lysis and Tumor Load in a Physiologic Model of Myeloma","volume":"29","author":"Endell","year":"2011","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0114-0","article-title":"Lenalidomide Enhances MOR202-Dependent Macrophage-Mediated Effector Functions via the Vitamin D Pathway","volume":"32","author":"Busch","year":"2018","journal-title":"Leukemia"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-279893","article-title":"Immunomodulatory Effects of Lenalidomide and Pomalidomide on Interaction of Tumor and Bone Marrow Accessory Cells in Multiple Myeloma","volume":"116","author":"Gorgun","year":"2010","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.exphem.2012.11.005","article-title":"Immunomodulatory Drugs Lenalidomide and Pomalidomide Inhibit Multiple Myeloma-Induced Osteoclast Formation and the RANKL\/OPG Ratio in the Myeloma Microenvironment Targeting the Expression of Adhesion Molecules","volume":"41","author":"Bolzoni","year":"2013","journal-title":"Exp Hematol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-850727","article-title":"IMiDs Prime Myeloma Cells for Daratumumab-Mediated Cytotoxicity Through Loss of Ikaros and Aiolos","volume":"132","author":"Fedele","year":"2018","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-770776","article-title":"Panobinostat Induces CD38 Upregulation and Augments the Antimyeloma Efficacy of Daratumumab","volume":"129","author":"Garcia-Guerrero","year":"2017","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0840-y","article-title":"Upregulation of CD38 Expression on Multiple Myeloma Cells by Novel HDAC6 Inhibitors Is a Class Effect and Augments the Efficacy of Daratumumab","volume":"35","author":"Garcia-Guerrero","year":"2020","journal-title":"Leukemia"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.25.15429","article-title":"Molecular Mechanism of Human CD38 Gene Expression by Retinoic Acid. Identification of Retinoic Acid Response Element in the First Intron","volume":"273","author":"Kishimoto","year":"1998","journal-title":"J Biol Chem"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 Expression and Complement Inhibitors Affect Response and Resistance to Daratumumab Therapy in Myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01603","article-title":"Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics","volume":"8","author":"Bannas","year":"2017","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2752","article-title":"Targeting Multiple Myeloma With AMG 424, a Novel Anti-CD38\/CD3 Bispecific T-Cell-Recruiting Antibody Optimized for Cytotoxicity and Cytokine Release","volume":"25","author":"Zuch de Zafra","year":"2019","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.242453","article-title":"Bi38-3 Is a Novel CD38\/CD3 Bispecific T-Cell Engager With Low Toxicity for the Treatment of Multiple Myeloma","volume":"106","author":"Fayon","year":"2021","journal-title":"Haematologica"},{"key":"B79","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1146\/annurev-immunol-030409-101302","article-title":"SLAM Family Receptors and SAP Adaptors in Immunity","volume":"29","author":"Cannons","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071755","article-title":"Roles of NK Cell Receptors 2b4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in Cancer","volume":"12","author":"Buller","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B81","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/ni.1693","article-title":"Influence of CRACC, a SLAM Family Receptor Coupled to the Adaptor EAT-2, on Natural Killer Cell Function","volume":"10","author":"Cruz-Munoz","year":"2009","journal-title":"Nat Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1128\/mcb.01107-14","article-title":"Immune Cell Inhibition by SLAMF7 Is Mediated by a Mechanism Requiring src Kinases, CD45, and SHIP-1 That Is Defective in Multiple Myeloma Cells","volume":"35","author":"Guo","year":"2015","journal-title":"Mol Cell Biol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200424917","article-title":"Molecular and Functional Characterization of a CS1 (CRACC) Splice Variant Expressed in Human NK Cells That Does Not Contain Immunoreceptor Tyrosine-Based Switch Motifs","volume":"34","author":"Lee","year":"2004","journal-title":"Eur J Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02551","article-title":"Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma","volume":"9","author":"Campbell","year":"2018","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-18-0579","article-title":"Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma","volume":"7","author":"Pazina","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20132038","article-title":"EAT-2, a SAP-Like Adaptor, Controls NK Cell Activation Through Phospholipase C\u03b3, Ca++, and Erk, Leading to Granule Polarization","volume":"211","author":"P\u00e9rez-Quintero","year":"2014","journal-title":"J Exp Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092184","article-title":"Fine Specificity and Molecular Competition in SLAM Family Receptor Signalling","volume":"9","author":"Wilson","year":"2014","journal-title":"PloS One"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1049","article-title":"Plasma Membrane Proteomics Identifies Biomarkers Associated With MMSET Overexpression in T(4;14) Multiple Myeloma","volume":"4","author":"Xie","year":"2013","journal-title":"Oncotarget"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2015.08.005","article-title":"Blimp-1\/PRDM1 Regulates the Transcription of Human CS1 (SLAMF7) Gene in NK and B Cells","volume":"221","author":"Kim","year":"2016","journal-title":"Immunobiology"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/nature22076","article-title":"SLAMF7 Is Critical for Phagocytosis of Haematopoietic Tumour Cells","volume":"544","author":"Chen","year":"2017","journal-title":"Via Mac-1 Integrin Nat"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26196","article-title":"Clinical Impact of Serum Soluble SLAMF7 in Multiple Myeloma","volume":"9","author":"Ishibashi","year":"2018","journal-title":"Oncotarget"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0525-6","article-title":"Soluble SLAMF7 Promotes the Growth of Myeloma Cells via Homophilic Interaction With Surface SLAMF7","volume":"34","author":"Kikuchi","year":"2020","journal-title":"Leukemia"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"B94","article-title":"CS1 (SLAMF7, CD319) Is an Effective Immunotherapeutic Target for Multiple Myeloma","volume":"7","author":"Malaer","year":"2017","journal-title":"Am J Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 Humanized Monoclonal Antibody HuLuc63 Inhibits Myeloma Cell Adhesion and Induces Antibody-Dependent Cellular Cytotoxicity in the Bone Marrow Milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-09-0483","article-title":"Combinatorial Efficacy of Anti-CS1 Monoclonal Antibody Elotuzumab (HuLuc63) and Bortezomib Against Multiple Myeloma","volume":"8","author":"van Rhee","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab Directly Enhances NK Cell Cytotoxicity Against Myeloma via CS1 Ligation: Evidence for Augmented NK Cell Function Complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017004382","article-title":"PD-1 Blockade Enhances Elotuzumab Efficacy in Mouse Tumor Models","volume":"1","author":"Bezman","year":"2017","journal-title":"Blood Adv"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12532","article-title":"Mechanisms of Action and Clinical Development of Elotuzumab","volume":"11","author":"Ritchie","year":"2018","journal-title":"Clin Transl Sci"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.04.003","article-title":"CS1, a SLAM Family Receptor Involved in Immune Regulation, Is a Therapeutic Target in Multiple Myeloma","volume":"88","author":"Veillette","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00262-014-1610-3","article-title":"Elotuzumab Enhances Natural Killer Cell Activation and Myeloma Cell Killing Through Interleukin-2 and TNF-\u03b1 Pathways","volume":"64","author":"Balasa","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-17-0344","article-title":"Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2020.101141","article-title":"CAR T and CAR NK Cells in Multiple Myeloma: Expanding the Targets","volume":"33","author":"Shah","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0998","article-title":"Antibody-Dependent Cellular Phagocytosis by Macrophages Is a Novel Mechanism of Action of Elotuzumab","volume":"17","author":"Kurdi","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v98.1.210","article-title":"Thalidomide and Immunomodulatory Derivatives Augment Natural Killer Cell Cytotoxicity in Multiple Myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"B106","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2015-01-625004","article-title":"Lenalidomide Augments Actin Remodeling and Lowers NK-Cell Activation Thresholds","volume":"126","author":"Lagrue","year":"2015","journal-title":"Blood"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"New Engl J Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","article-title":"Elotuzumab, Lenalidomide, and Dexamethasone in RRMM: Final Overall Survival Results From the Phase 3 Randomized ELOQUENT-2 Study","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab Plus Pomalidomide and Dexamethasone for Multiple Myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"New Engl J Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.tps8113","article-title":"ELOQUENT-1: A Phase III, Randomized, Open-Label Trial of Lenalidomide\/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma (CA204-006)","volume":"30","author":"Dimopoulos","year":"2012","journal-title":"J Clin Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.02.004","article-title":"Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient","volume":"19","author":"Ghobrial","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00544","article-title":"Anti-CS1 \u00d7 Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1(+) Myeloma Cells and Release Type-1 Cytokines","volume":"10","author":"Lum","year":"2020","journal-title":"Front Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-021-00254-w","article-title":"CARAMBA: A First-in-Human Clinical Trial With SLAMF7 CAR-T Cells Prepared by Virus-Free Sleeping Beauty Gene Transfer to Treat Multiple Myeloma","author":"Prommersberger","year":"2021","journal-title":"Gene Ther"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19123924","article-title":"Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update","volume":"19","author":"Abramson","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-1431","article-title":"First-In-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7\/CS1 in Patients With Relapsed and Refractory Multiple Myeloma","volume":"26","author":"Vij","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107982","article-title":"Stromal Cell-Contact Dependent PI3K and APRIL Induced NF-\u03baB Signaling Prevent Mitochondrial- and ER Stress Induced Death of Memory Plasma Cells","volume":"32","author":"Cornelis","year":"2020","journal-title":"Cell Rep"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.6.3655","article-title":"Cutting Edge: The Dependence of Plasma Cells and Independence of Memory B Cells on BAFF and APRIL","volume":"180","author":"Benson","year":"2008","journal-title":"J Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(02)00389-8","article-title":"Blood Dendritic Cells Interact With Splenic Marginal Zone B Cells to Initiate T-Independent Immune Responses","volume":"17","author":"Bal\u00e1zs","year":"2002","journal-title":"Immunity"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707547","article-title":"Osteoclasts Promote Immune Suppressive Microenvironment in Multiple Myeloma: Therapeutic Implication","volume":"128","author":"An","year":"2016","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA Promote Human Multiple Myeloma Growth and Immunosuppression in the Bone Marrow Microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/22.7.1147","article-title":"The BCMA Gene, Preferentially Expressed During B Lymphoid Maturation, Is Bidirectionally Transcribed","volume":"22","author":"Laabi","year":"1994","journal-title":"Nucleic Acids Res"},{"key":"B122","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41408-020-0337-y","article-title":"B-Cell Maturation Antigen Expression Across Hematologic Cancers: A Systematic Literature Review","volume":"10","author":"Dogan","year":"2020","journal-title":"Blood Cancer J"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1016\/j.celrep.2019.10.097","article-title":"IRF4 Activity Is Required in Established Plasma Cells to Regulate Gene Transcription and Mitochondrial Homeostasis","volume":"29","author":"Low","year":"2019","journal-title":"Cell Rep"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01078-0","article-title":"The Transcription Factor IRF4 Represses Proapoptotic BMF and BIM to Licence Multiple Myeloma Survival","author":"Fedele","year":"2020","journal-title":"Leukemia"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2527","article-title":"Mcl-1 Is Essential for the Survival of Plasma Cells","volume":"14","author":"Peperzak","year":"2013","journal-title":"Nat Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1126\/science.1061964","article-title":"An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway","volume":"293","author":"Schiemann","year":"2001","journal-title":"Science"},{"key":"B128","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1128\/cmr.00046-17","article-title":"The Role of BAFF System Molecules in Host Response to Pathogens","volume":"30","author":"Sakai","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031330","article-title":"BCMA Is Essential for the Survival of Long-Lived Bone Marrow Plasma Cells","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J Exp Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-110874","article-title":"TACI, Unlike BAFF-R, Is Solely Activated by Oligomeric BAFF and APRIL to Support Survival of Activated B Cells and Plasmablasts","volume":"111","author":"Bossen","year":"2008","journal-title":"Blood"},{"key":"B131","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1172\/jci14121","article-title":"Association of BAFF\/BLyS Overexpression and Altered B Cell Differentiation With Sj\u00f6gren\u2019s Syndrome","volume":"109","author":"Groom","year":"2002","journal-title":"J Clin Invest"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice Transgenic for BAFF Develop Lymphocytic Disorders Along With Autoimmune Manifestations","volume":"190","author":"Mackay","year":"1999","journal-title":"J Exp Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1172\/jci33760","article-title":"APRIL Secreted by Neutrophils Binds to Heparan Sulfate Proteoglycans to Create Plasma Cell Niches in Human Mucosa","volume":"118","author":"Huard","year":"2008","journal-title":"J Clin Invest"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1096\/fj.08-124669","article-title":"The Proteoglycan (Heparan Sulfate Proteoglycan) Binding Domain of APRIL Serves as a Platform for Ligand Multimerization Andcross-Linking","volume":"23","author":"Kimberley","year":"2009","journal-title":"FASEB J"},{"key":"B135","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase Directly Sheds the Survival Receptor BCMA From Plasma Cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-15-2224","article-title":"Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma","volume":"22","author":"Sanchez","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14145","article-title":"Evaluation of B Cell Maturation Antigen as a Target for Antibody Drug Conjugate Mediated Cytotoxicity in Multiple Myeloma","volume":"174","author":"Lee","year":"2016","journal-title":"Br J Haematol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0278-7","article-title":"Preclinical Assessment of an Antibody-PBD Conjugate That Targets BCMA on Multiple Myeloma and Myeloma Progenitor Cells","volume":"33","author":"Kinneer","year":"2019","journal-title":"Leukemia"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-Cell Maturation Antigen Is Elevated in Multiple Myeloma and Correlates With Disease Status and Survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br J Haematol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-Cell Maturation Antigen: A Novel Biomarker to Predict Outcomes for Multiple Myeloma Patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16752","article-title":"Normalization of Serum B-Cell Maturation Antigen Levels Predicts Overall Survival Among Multiple Myeloma Patients Starting Treatment","volume":"92","author":"Jew","year":"2020","journal-title":"Br J Haematol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox097","article-title":"Soluble TACI and Soluble BCMA as Biomarkers in Primary Central Nervous System Lymphoma","volume":"19","author":"Thaler","year":"2017","journal-title":"Neuro Oncol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2019.1586539","article-title":"Anti-BCMA Antibodies in the Future Management of Multiple Myeloma","volume":"19","author":"Gavriatopoulou","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2016.1186644","article-title":"Emerging Antibodies for the Treatment of Multiple Myeloma","volume":"21","author":"Zagouri","year":"2016","journal-title":"Expert Opin Emerg Drugs"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13000","article-title":"Dose-Escalation Study of Tabalumab With Bortezomib and Dexamethasone in Japanese Patients With Multiple Myeloma","volume":"107","author":"Iida","year":"2016","journal-title":"Cancer Sci"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-0201","article-title":"Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"22","author":"Raje","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14483","article-title":"Phase 2 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma","volume":"176","author":"Raje","year":"2017","journal-title":"Br J Haematol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102284","article-title":"Neutrophils Contribute to Excess Serum BAFF Levels and Promote CD4+ T Cell and B Cell Responses in Lupus-Prone Mice","volume":"9","author":"Coquery","year":"2014","journal-title":"PloS One"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2009.04007.x","article-title":"BAFF: A Local and Systemic Target in Autoimmune Diseases","volume":"158","author":"Moisini","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL Protect Myeloma Cells From Apoptosis Induced by Interleukin 6 Deprivation and Dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315608254","article-title":"Association of BAFF, APRIL Serum Levels, BAFF-R, TACI and BCMA Expression on Peripheral B-Cell Subsets With Clinical Manifestations in Systemic Lupus Erythematosus","volume":"25","author":"Salazar-Camarena","year":"2016","journal-title":"Lupus"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.02657","article-title":"Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J Clin Oncol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134063","article-title":"A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE\u00ae (Bispecific T-Cell Engager) Molecule, in Relapsed\/Refractory (RR) Multiple Myeloma (MM)","volume":"136","author":"Harrison","year":"2020","journal-title":"Blood"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122895","article-title":"First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2 + 1 T Cell Engager (TCE) CC-93269 in Patients (Pts) With Relapsed\/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139893","article-title":"Initial Results of a Phase I Study of TNB-383B, a BCMA X CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Rodriguez","year":"2020","journal-title":"Blood"},{"key":"B156","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1182\/blood-2020-133355","article-title":"Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients With Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"136","author":"Lesokhin","year":"2020","journal-title":"Blood"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-138831","article-title":"Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) X CD3 Bispecific Antibody, in Relapsed and\/or Refractory Multiple Myeloma (RRMM)","volume":"136","author":"Garfall","year":"2020","journal-title":"Blood"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139192","article-title":"REGN5458, a BCMA X CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients With Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"136","author":"Madduri","year":"2020","journal-title":"Blood"},{"key":"B159","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody-Drug Conjugate, GSK2857916, in Relapsed\/Refractory Multiple Myeloma: An Update on Safety and Efficacy From Dose Expansion Phase I Study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30788-0","article-title":"Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma (DREAMM-2): A Two-Arm, Randomised, Open-Label, Phase 2 Study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0834-9","article-title":"Phase 1 Study of the Anti-BCMA Antibody-Drug Conjugate AMG 224 in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"35","author":"Lee","year":"2021","journal-title":"Leukemia"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136375","article-title":"Phase 1, First-In-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"B163","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41375-019-0669-4","article-title":"Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma: Can We do Better","volume":"34","author":"D\u2019Agostino","year":"2020","journal-title":"Leukemia"},{"key":"B164","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13046-017-0667-1","article-title":"Fate of Antibody-Drug Conjugates in Cancer Cells","volume":"37","author":"Chalouni","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"B165","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/jcp.28967","article-title":"Potential Drugs Used in the Antibody-Drug Conjugate (ADC) Architecture for Cancer Therapy","volume":"235","author":"Yaghoubi","year":"2020","journal-title":"J Cell Physiol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.2174\/1574884712666180802095521","article-title":"Antibody-Drug Conjugates: A Review on the Epitome of Targeted Anti- Cancer Therapy","volume":"13","author":"Hasan","year":"2018","journal-title":"Curr Clin Pharmacol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.3390\/ph13090245","article-title":"Antibody-Drug Conjugates: The Last Decade","volume":"13","author":"Joubert","year":"2020","journal-title":"Pharm (Basel)"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-05-4489","article-title":"Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing","volume":"66","author":"Erickson","year":"2006","journal-title":"Cancer Res"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional Interaction of Plasmacytoid Dendritic Cells With Multiple Myeloma Cells: A Therapeutic Target","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel Anti-B-Cell Maturation Antigen Antibody-Drug Conjugate (GSK2857916) Selectively Induces Killing of Multiple Myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30576-x","article-title":"Targeting B-Cell Maturation Antigen With GSK2857916 Antibody-Drug Conjugate in Relapsed or Refractory Multiple Myeloma (BMA117159): A Dose Escalation and Expansion Phase 1 Trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17235","article-title":"Focus on Monoclonal Antibodies Targeting B-Cell Maturation Antigen (BCMA) in Multiple Myeloma: Update 2021","volume":"193","author":"Demel","year":"2021","journal-title":"Br J Haematol"},{"key":"B173","doi-asserted-by":"publisher","first-page":"28","DOI":"10.23736\/s0031-0808.20.04121-x","article-title":"BCMA-Targeting Approaches for Treatment of Multiple Myeloma","volume":"63","author":"Chen","year":"2021","journal-title":"Panminerva Med"},{"key":"B174","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40779-021-00302-x","article-title":"Immunotherapeutic Strategies Targeting B Cell Maturation Antigen in Multiple Myeloma","volume":"8","author":"Fang","year":"2021","journal-title":"Mil Med Res"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-021-00624-6","article-title":"Antibody-Based Treatment Approaches in Multiple Myeloma","volume":"16","author":"Hosoya","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"B176","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/14737140.2021.1837627","article-title":"Monoclonal Antibodies as an Addition to Current Myeloma Therapy Strategies","volume":"21","author":"Jullien","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"B177","article-title":"Antibody Treatment in Multiple Myeloma","volume":"19","author":"Maples","year":"2021","journal-title":"Clin Adv Hematol Oncol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14712598.2021.1872540","article-title":"An Update on B-Cell Maturation Antigen-Targeted Therapies in Multiple Myeloma","volume":"13","author":"Martino","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1177\/2040620721989585","article-title":"B-Cell Maturation Antigen (BCMA) in Multiple Myeloma: The New Frontier of Targeted Therapies","volume":"12","author":"Sanchez","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.23736\/s0031-0808.20.04149-x","article-title":"Monoclonal Antibodies in Multiple Myeloma","volume":"63","author":"Vozella","year":"2021","journal-title":"Panminerva Med"},{"key":"B181","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal Epithelial Findings in Patients With Multiple Myeloma Treated With Antibody\u2013Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.235937","article-title":"Characterization of Response and Corneal Events With Extended Follow-Up After Belantamab Mafodotin (GSK2857916) Monotherapy for Patients With Relapsed Multiple Myeloma: A Case Series From the First-Time-in-Human Clinical Trial","volume":"105","author":"Popat","year":"2020","journal-title":"Haematologica"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-17-3202","article-title":"Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody-Drug Conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res"},{"key":"B184","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"Usmani SZ. B-Cell Maturation Antigen (BCMA) in Multiple Myeloma: Rationale for Targeting and Current Therapeutic Approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01155","article-title":"Targeted Therapy With Immunoconjugates for Multiple Myeloma","volume":"11","author":"Bruins","year":"2020","journal-title":"Front Immunol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000110","article-title":"Bispecifics, Trispecifics, and Other Novel Immune Treatments in Myeloma","volume":"2020","author":"Lancman","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.3390\/ph14010040","article-title":"Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies Off the Shelf","volume":"14","author":"Baril\u00e0","year":"2021","journal-title":"Pharm (Basel)"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddtec.2018.08.005","article-title":"Amanitins and Their Development as a Payload for Antibody-Drug Conjugates","volume":"30","author":"Pahl","year":"2018","journal-title":"Drug Discovery Today Technol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-Cell Engagers for Cancer Immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol Cell Biol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (Bispecific T-Cell Engager) Platform: Development and Future Potential of a Targeted Immuno-Oncology Therapy Across Tumor Types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"key":"B191","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/ftd.0000000000000681","article-title":"Monoclonal Antibody Monitoring: Clinically Relevant Aspects, A Systematic Critical Review","volume":"42","author":"Regazzi","year":"2020","journal-title":"Ther Drug Monit"},{"key":"B192","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/ftd.0000000000000668","article-title":"Key Features Defining the Disposition of Bispecific Antibodies and Their Efficacy In Vivo","volume":"42","author":"Golay","year":"2020","journal-title":"Ther Drug Monit"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2018-0259","article-title":"Immunogenicity of Antibody\u2013Drug Conjugates: Observations Across 8 Molecules in 11 Clinical Trials","volume":"11","author":"Carrasco-Triguero","year":"2019","journal-title":"Bioanalysis"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00501","article-title":"Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions","volume":"11","author":"Caraccio","year":"2020","journal-title":"Front Immunol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.26233","article-title":"Production of Stable Bispecific IgG1 by Controlled Fab-Arm Exchange: Scalability From Bench to Large-Scale Manufacturing by Application of Standard Approaches","volume":"5","author":"Gramer","year":"2013","journal-title":"MAbs"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183390","article-title":"Bispecific T Cell Engager (BiTE\u00ae) Antibody Constructs can Mediate Bystander Tumor Cell Killing","volume":"12","author":"Ross","year":"2017","journal-title":"PloS One"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.388","article-title":"A Novel BCMA\/CD3 Bispecific T-Cell Engager for the Treatment of Multiple Myeloma Induces Selective Lysis","volume":"31","author":"Hipp","year":"2017","journal-title":"Vitro Vivo Leuk"},{"key":"B198","doi-asserted-by":"publisher","first-page":"28","DOI":"10.23736\/s0031-0808.20.04121-x","article-title":"BCMA-Targeting Approaches for Treatment of Multiple Myeloma","volume":"63","author":"Chen","year":"2020","journal-title":"Panminerva Med"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002565","article-title":"AMG 701 Induces Cytotoxicity of Multiple Myeloma Cells and Depletes Plasma Cells in Cynomolgus Monkeys","volume":"4","author":"Goldstein","year":"2020","journal-title":"Blood Adv"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002524","article-title":"The Immunomodulatory Drugs Lenalidomide and Pomalidomide Enhance the Potency of AMG 701 in Multiple Myeloma Preclinical Models","volume":"4","author":"Cho","year":"2020","journal-title":"Blood Adv"},{"key":"B201","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.8034","article-title":"Pre-Clinical Development of TNB-383B, a Fully Human T-Cell Engaging Bispecific Antibody Targeting BCMA for the Treatment of Multiple Myeloma","volume":"36","author":"Buelow","year":"2018","journal-title":"J Clin Oncol"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.69","article-title":"Ex Vivo Efficacy of BCMA-Bispecific Antibody TNB-383B in Relapsed\/Refractory Multiple Myeloma","volume":"1","author":"Foureau","year":"2020","journal-title":"eJHaem"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-121805","article-title":"Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics From a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients With Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"134","author":"Raje","year":"2019","journal-title":"Blood"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G Protein-Coupled Receptor 5D in the Bone Marrow Is Associated With Poor Prognosis in Patients With Multiple Myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5\/CD3 and Is a Requirement for Myeloma Cell Killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136985","article-title":"Initial Clinical Activity and Safety of BFCR4350A, a FcRH5\/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Cohen","year":"2020","journal-title":"Blood"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136980","article-title":"Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5\/CD3 T-Cell-Engaging Bispecific Antibody, in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Nakamura","year":"2020","journal-title":"Blood"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1126\/science.1144603","article-title":"Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange","volume":"317","author":"van der Neut Kolfschoten","year":"2007","journal-title":"Science"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.29004","article-title":"Opening the Door to Innovation","volume":"6","author":"Schuurman","year":"2014","journal-title":"MAbs"},{"key":"B211","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific Antibodies: A Mechanistic Review of the Pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1553","article-title":"Therapeutic IgG4 Antibodies Engage in Fab-Arm Exchange With Endogenous Human IgG4 in vivo","volume":"27","author":"Labrijn","year":"2009","journal-title":"Nat Biotechnol"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1220145110","article-title":"Efficient Generation of Stable Bispecific IgG1 by Controlled Fab-Arm Exchange","volume":"110","author":"Labrijn","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2014.169","article-title":"Controlled Fab-Arm Exchange for the Generation of Stable Bispecific Igg1","volume":"9","author":"Labrijn","year":"2014","journal-title":"Nat Protoc"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002393","article-title":"Teclistamab Is an Active T Cell-Redirecting Bispecific Antibody Against B-Cell Maturation Antigen for Multiple Myeloma","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-2299","article-title":"Preclinical Activity of JNJ-7957, a Novel BCMA\u00d7CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113921","article-title":"Preclinical and Nonclinical Characterization of HPN217: A Tri-Specific T Cell Activating Construct (TriTAC) Targeting B Cell Maturation Antigen (BCMA) for the Treatment of Multiple Myeloma","volume":"132","author":"Law","year":"2018","journal-title":"Blood"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.8045","article-title":"AFM26 Is a Novel, Highly Potent BCMA\/CD16A-Directed Bispecific Antibody for High Affinity NK-Cell Engagement in Multiple Myeloma","volume":"35","author":"Gantke","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118970","article-title":"Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma","volume":"132","author":"Ross","year":"2018","journal-title":"Blood"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128749","article-title":"CTX-8573, an Innate-Cell Engager Targeting BCMA, Is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma","volume":"134","author":"Watkins-Yoon","year":"2019","journal-title":"Blood"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000320","article-title":"BCMA-Targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-Enhanced Efficacy Against Multiple Myeloma","volume":"43","author":"Wang","year":"2020","journal-title":"J Immunother"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma","volume":"21","author":"Gorgun","year":"2015","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 Axis Modulates the Natural Killer Cell Versus Multiple Myeloma Effect: A Therapeutic Target for CT-011, a Novel Monoclonal Anti-PD-1 Antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.213","article-title":"Marrow Stromal Cells Induce B7-H1 Expression on Myeloma Cells, Generating Aggressive Characteristics in Multiple Myeloma","volume":"27","author":"Tamura","year":"2013","journal-title":"Leukemia"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab Versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"New Engl J Med"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 Blockade With Nivolumab in Relapsed or Refractory Hodgkin\u2019s Lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"New Engl J Med"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31821ca6ce","article-title":"PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-Cell Responses to Autologous Dendritic Cell\/Myeloma Fusion Vaccine","volume":"34","author":"Rosenblatt","year":"2011","journal-title":"J\u00a0Immunother"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.03.011","article-title":"Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade","volume":"17","author":"Hallett","year":"2011","journal-title":"Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202005","article-title":"Programmed Death Receptor-1\/Programmed Death Receptor Ligand-1 Blockade After Transient Lymphodepletion to Treat Myeloma","volume":"190","author":"Kearl","year":"2013","journal-title":"J Immunol"},{"key":"B230","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.3390\/jcm9113577","article-title":"CAR T-Cells in Multiple Myeloma Are Ready for Prime Time","volume":"9","author":"Rodr\u00edguez-Otero","year":"2020","journal-title":"J Clin Med"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004176","article-title":"What Is the Future of Immunotherapy in Multiple Myeloma","volume":"136","author":"Rasche","year":"2020","journal-title":"Blood"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1200\/op.21.00032","article-title":"Immunotherapy in Multiple Myeloma\u2014Time for a Second Major Paradigm Shift","volume":"18","author":"Mohan","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00699","article-title":"Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives","volume":"9","author":"Romano","year":"2019","journal-title":"Front Oncol"},{"key":"B234","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1038\/s41598-020-58859-x","article-title":"High-Density Neutrophils in MGUS and Multiple Myeloma Are Dysfunctional and Immune-Suppressive Due to Increased STAT3 Downstream Signaling","volume":"10","author":"Romano","year":"2020","journal-title":"Sci Rep"},{"key":"B235","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-Cell RNA Sequencing Reveals Compromised Immune Microenvironment in Precursor Stages of Multiple Myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"key":"B236","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood.2019004537","article-title":"Immunogenomic Identification and Characterization of Granulocytic Myeloid-Derived Suppressor Cells in Multiple Myeloma","volume":"136","author":"Perez","year":"2020","journal-title":"Blood"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7969","article-title":"Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) Are Increased in Multiple Myeloma and Are Driven by Dysfunctional Mesenchymal Stem Cells (MSC)","volume":"7","author":"Giallongo","year":"2016","journal-title":"Oncotarget"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2018.1470929","article-title":"PMN-MDSC and Arginase Are Increased in Myeloma and may Contribute to Resistance to Therapy","volume":"18","author":"Romano","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12962","article-title":"Monoclonal Antibody-Mediated Killing of Tumour Cells by Neutrophils","author":"Heemskerk","year":"2018","journal-title":"Eur J Clin Invest"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2020.04.012","article-title":"Recent Advances of Antibody Drug Conjugates for Clinical Applications","volume":"10","author":"Zhao","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"B241","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s42003-020-01558-0","article-title":"Combinatorial Targeting of Multiple Myeloma by Complementing T Cell Engaging Antibody Fragments","volume":"4","author":"Geis","year":"2021","journal-title":"Commun Biol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.684561\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T09:21:11Z","timestamp":1672737671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.684561\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":241,"alternative-id":["10.3389\/fonc.2021.684561"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.684561","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]},"article-number":"684561"}}